Antibody

2012 was the year of the antibody developer

Saturday 19 January 2013

Interviewee/Contributer: William Ellington

Organisation: MedNous

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Antibodies and ADCs lead cancer pipeline

Saturday 19 May 2012

Interviewee/Contributer: Bruno Pagliara

Organisation: On-Kos Pharma Consulting

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Interview: 4-Antibody AG - How do you structure a biotech for divestment?

Friday 27 April 2012

Interviewee/Contributer: Robert Burns

Organisation: 4-Antibody AG

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Kymab unlocks the power of the mouse

Saturday 24 March 2012

Interviewee/Contributer: Andrew Sandham

Organisation: Kymab Ltd

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Europe to tackle antimicrobial resistance

Friday 20 January 2012

Interviewee/Contributer: Karen Finn

Organisation: MedNous

Full text available to subscribers only. Click here for information on subscribing to MedNous.

The perilous state of antibiotic development

Friday 20 January 2012

Interviewee/Contributer: Helen Boucher

Organisation: Infectious Diseases Society of America (IDSA)

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Advancing a modular approach to antibody design

Sunday 23 October 2011

Interviewee/Contributer: Kevin FitzGerald

Organisation: F-Star GmbH

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Antibodies show promise against influenza

Saturday 22 October 2011

Interviewee/Contributer: Antonio Lanzavecchia

Organisation: Humabs BioMed SA

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Developing biosimilar monoclonal antibodies will not be easy

Wednesday 23 March 2011

Interviewee/Contributer: Gabriele Schaffner-Dallmann

Organisation: Pharmatching GmbH

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Syphogen sees opportunities in antibody mixtures

Tuesday 22 March 2011

Interviewee/Contributer: Kirsten Drejer

Organisation: Symphogen A/S

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Syndicate content